Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae

• Published in: Scientific reports Vol. 11; no. 1; pp. 18 - 8
• Main Authors: Katip, Wasan, Yoodee, Jukapun, Uitrakul, Suriyon, Oberdorfer, Peninnah
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.01.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308; 692/699; Antibiotics; Bacteremia; Carbapenems; Colistin; Drug dosages; Drug therapy; E coli; Enterobacteriaceae; Humanities and Social Sciences; Infections; Intra-abdominal infection; Mortality; multidisciplinary; Patients; Science; Science (multidisciplinary); Urinary tract; β Lactamase
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-78098-4

Colistin provides in vitro activity against numerous ESBL-producing and carbapenem-resistant bacteria. However, clinical information with respect to its utilization in infection caused by ESBL producers is limited. The aim of this study was a comparison of mortality rates of loading dose (LD) colistin and carbapenems as definitive therapies in a cohort of patients with infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae . A retrospective cohort study in 396 patients with ESBL-producing E.coli and K.pneumoniae infection at a university-affiliated hospital was conducted between 1 January 2005 and 30 June 2015 to compare outcomes of infected patients who received LD colistin (95 patients) with carbapenems (301 patients). The three primary outcomes were 30-day mortality, clinical response and microbiological response. The most common infection types were urinary tract infection (49.49%), followed by pneumonia (40.66%), bacteremia (13.64%), skin and soft tissue infections (4.80%) and intra-abdominal infection (3.03%). LD colistin group provided higher 30-day mortality when compared with carbapenems group (HR 7.97; 95% CI 3.68 to 17.25; P  = 0.001). LD colistin was also independently associated with clinical failure (HR 4.30; 95% CI 1.93 to 9.57; P  = 0.001) and bacteriological failure (HR 9.49; 95% CI 3.76 to 23.96; P  = 0.001) when compared with those who received carbapenems. LD colistin treatment was associated with poorer outcomes, i.e. mortality rate, clinical response and microbiological response. Moreover, when adjusted confounding factors, LD colistin was still less effective than carbapenems. It should be noted that, however, the use of Vitek-2 to assess colistin susceptibility could provide inaccurate results. Also, the difference in baseline characteristics could still remain in retrospective study although compensation by hazard ratio adjustment was performed. Therefore, clinical utilization of LD colistin should be recommended as an alternative for treatment ESBL-producing Enterobacteriaceae only in the circumstances where carbapenems cannot be utilized, but this recommendation must be considered carefully.